Immunocore Holdings plc
IMCR · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $248 | $249 | $144 | $36 |
| % Growth | -0.7% | 72.9% | 295.3% | – |
| Cost of Goods Sold | $8 | $1 | $5 | $0 |
| Gross Profit | $239 | $248 | $139 | $36 |
| % Margin | 96.6% | 99.6% | 96.3% | 100% |
| R&D Expenses | $177 | $164 | $84 | $100 |
| G&A Expenses | $0 | $0 | $0 | $119 |
| SG&A Expenses | $0 | $144 | $0 | $111 |
| Sales & Mktg Exp. | $0 | $0 | $0 | -$8 |
| Other Operating Expenses | $118 | $0 | $97 | $0 |
| Operating Expenses | $296 | $308 | $182 | $211 |
| Operating Income | -$56 | -$60 | -$43 | -$175 |
| % Margin | -22.7% | -23.9% | -29.7% | -478.5% |
| Other Income/Exp. Net | $14 | -$1 | $9 | -$5 |
| Pre-Tax Income | -$42 | -$61 | -$34 | -$180 |
| Tax Expense | -$1 | -$6 | $10 | $0 |
| Net Income | -$41 | -$55 | -$43 | -$180 |
| % Margin | -16.5% | -22.2% | -30.1% | -493.4% |
| EPS | -1.02 | -1.13 | -0.95 | -3.13 |
| % Growth | 9.7% | -18.9% | 69.6% | – |
| EPS Diluted | -1.02 | -1.13 | -0.95 | -3 |
| Weighted Avg Shares Out | 50 | 49 | 46 | 42 |
| Weighted Avg Shares Out Dil | 50 | 49 | 46 | 44 |
| Supplemental Information | – | – | – | – |
| Interest Income | $26 | $18 | $4 | $0 |
| Interest Expense | $19 | $5 | $5 | $6 |
| Depreciation & Amortization | $3 | $4 | $4 | $8 |
| EBITDA | -$39 | -$52 | -$38 | -$167 |
| % Margin | -15.5% | -20.7% | -26.6% | -457% |